A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection

Howard Bailey, R. Timothy Mulcahy, Kendra D. Tutsch, Jack M. Rozental, Dona Alberti, Rhoda Z. Arzoomanian, Mary B. Tombes, Donald L. Trump, George Wilding

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

SR-2508, a less lipophilic and neurotoxic analogue of the nitroimidazole, misonidazole, has exhibited significant chemosensitization proper ties in preclinical studies with alkylating agents. A phase I trial was carried out to assess toxicity and possible pharmacological interactions of the combination of short infusions of SR-2508 and cyclophosphamide (CP). Patients were randomly assigned to receive either CP alone followed in 3 wk by CP + SR-2508, or CP + SR-2508 followed by CP alone. All additional courses were CP + SR-2508. The maximum tolerated dose of the combination was determined by dose escalation of SR-2508 while the dose of CP remained fixed, initially 1.0 u nr. and then a second maximum tolerated dose was determined with CP at 1.6 g/m2. One hundred seven teen Ã

Original languageEnglish (US)
Pages (from-to)1099-1104
Number of pages6
JournalCancer Research
Volume51
Issue number4
StatePublished - Feb 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase I Study of SR-2508 and Cyclophosphamide Administered by Intravenous Injection'. Together they form a unique fingerprint.

Cite this